Breckenridge Announces Final Approval of its ANDA for Roflumilast Tablets (Daliresp®)

Saturday, October 6, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOCA RATON, Fla., Oct. 5, 2018 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food

and Drug Administration has granted final approval for its Abbreviated New Drug Application for Roflumilast Tablets, 500mcg, generic for Daliresp® Tablets by AstraZeneca Pharmaceutical LP.  Breckenridge's Roflumilast Tablets product was developed by
Ferrer Internacional, S.A.

Roflumilast Tablets are a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Daliresp® generated annual sales of $211,000,000 during the year ended August 31, 2018, according to industry sales data.

AstraZeneca, Breckenridge, and Ferrer have entered into a confidential settlement agreement regarding the Hatch-Waxman litigation for Roflumilast.  Breckenridge, as authorized by the settlement agreement, may sell or offer to sell Roflumilast at a later date. Further announcements will be made prior to product launch.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.  ww.bpirx.com

About Ferrer

Founded in 1959, Ferrer is a privately-held international chemical-pharmaceutical company headquartered in Barcelona. It is active throughout the full value chain, from R&D to international marketing. It is present in more than 110 countries, with 19 international affiliates. It is active in the pharmaceutical, health, fine chemical and food sectors, key areas for contributing to people's health and wellbeing.

Since the beginning, Ferrer has been committed to the research and development of innovative medicinal products and to maintain a solid industrial structure. Ferrer's activity across the entire healthcare spectrum includes prescription drugs, hospital products, diagnostics, vaccines, as well as fine chemicals, food and feed. For more information, visit www.ferrer.com.

DALIRESP is a registered of the AstraZeneca group of companies

Cision View original content:http://www.prnewswire.com/news-releases/breckenridge-announces-final-approval-of-its-anda-for-roflumilast-tablets-daliresp-300725337.html

SOURCE Breckenridge Pharmaceutical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store